Spinal cord stimulation for neuropathic pain: current perspectives

Tilman Wolter
Interdisciplinary Pain Centre, University Hospital Freiburg, Freiburg, Germany

Abstract: Neuropathic pain constitutes a significant portion of chronic pain. Patients with neuropathic pain are usually more heavily burdened than patients with nociceptive pain. They suffer more often from insomnia, anxiety, and depression. Moreover, analgesic medication often has an insufficient effect on neuropathic pain. Spinal cord stimulation constitutes a therapy alternative that, to date, remains underused. In the last 10 to 15 years, it has undergone constant technical advancement. This review gives an overview of the present practice of spinal cord stimulation for chronic neuropathic pain and current developments such as high-frequency stimulation and peripheral nerve field stimulation.

Keywords: spinal cord stimulation, neuropathic pain, neurostimulation

Introduction
Neuropathic pain constitutes a significant portion of chronic pain. The International Association for the Study of Pain defines neuropathic pain as pain caused by a lesion or disease of the somatosensory nervous system. Patients with neuropathic pain usually are more heavily burdened than patients with nociceptive pain and suffer more often from insomnia, anxiety, and depression. Moreover, analgesic medication often has an insufficient effect on neuropathic pain.

Spinal cord stimulation (SCS) constitutes a therapy alternative that, to date, remains underused. It was described for the first time in 1967 and has become a standard therapy in many hospitals since the middle of the 1980s. Nonetheless, there is still a significant underuse of this treatment. In the last 10–15 years, SCS has undergone constant technical advancement. Stimulation patterns can now be adjusted according to the patient’s needs, thus increasing the efficacy of stimulation.

SCS for the treatment of pain must be seen in the general context of neuromodulative therapies. Neuromodulation has undergone rapid development in the last few years. Today, neurostimulation systems are used not only in the therapy of chronic pain but also in a multitude of different disorders, such as epilepsy, psychiatric diseases, and movement disorders, as well as gastrointestinal and urological diseases. This review gives an overview of the present practice of SCS for chronic neuropathic pain and current developments in the field.

Outline of the history of SCS and its uses
The development of SCS was one of the consequences of the gate control theory of Melzack and Wall. They stated that external and internal pain stimuli are recorded...
by pain receptors in the skin, muscles, joints, and internal organs and switched to the second neuron of the pain pathway within the dorsal horn of the spinal cord. Here, many peripheral neurons converge to a single neuron termed the wide dynamic range neuron. According to their theory, activation of myelinated Aβ fibers inhibits pain transmission and is enhanced by activation of thinly myelinated Aδ fibers and unmyelinated C fibers.

Shealy et al employed SCS in 1967 for the first time in an animal model, using a technique that they termed dorsal column stimulation at that time. They showed that dorsal column stimulation, as well as stimulation of the anterior spinocerebellar tract, inhibited paw withdrawal after painful stimuli in cats. In the same year, they treated a patient who suffered from intractable pain resulting from a progressive-state inoperable bronchial carcinoma. Electrode implantation was performed over a thoracic laminectomy at the level TH 2/3. After starting the stimulation, pain was drastically reduced and analgetic medication could be stopped. The patient died after 6 days from a previously undetected bacterial endocarditis. In 1970, Shealy et al published a series of six patients with various diagnoses who had been treated with SCS; three of them had a very good outcome.

Nashold and Friedman published the first larger study on SCS in 1972. In this study, patients with neuropathic pain responded better to stimulation than patients with nociceptive pain such as bone pain, joint pain, and discal pain. The same year, a two-step procedure with percutaneous testing of the electrode before final implantation of the impulse generator was proposed by Hosobuchi et al. A study of 50 patients published in 1974 showed that SCS led to better results in phantom pain than in peripheral nerve lesions. Before 1980, intra- or subdural electrodes were often employed, sometimes leading to grave complications such as intraspinal bleeding or spinal cord damage. Therefore, great caution is required in comparing the treatment data from that time with those of our time.

**Mechanisms of action**

The first explanation of the effects of SCS according to the gate control theory was that the nociceptive signal in the dorsal horn would be inhibited by antidromic activation of collateral fibers of the dorsal columns. This explanation later turned out to be only partially true. According to this explanation, acute nociceptive pain would be inhibited most effectively by SCS, which in fact is not the case. In addition, the pain-free interval after cessation of stimulation cannot be explained in that way. Apparently, there is also an orthodromic stimulation, which becomes manifest in the paresthesia felt by the patient under stimulation. Supraspinal centers are also involved in SCS effects. At the time the gate control theory was first described, there was only a little knowledge about supraspinal control of pain transmission, and SCS was thought to act at the segmental level.

In animal models, a couple of possible mechanisms of action have been described. Overexcitability of wide dynamic range (WDR) neurons in the dorsal horn can at least partially be overcome by SCS. This seems to be related to an increased basal release of glutamate and to a dysfunction of the γ-amino butyric acid (GABA) system. SCS counteracts this mechanism by increased GABA release. However, GABA release was only observed in animals that also had pain relief effected by SCS. Moreover, SCS led to a decreased extracellular glutamate concentration in the dorsal horn. Here, activation of the GABAA receptor seems to play a crucial role. Cholinergic transmitter systems are also involved in SCS effects. Release of acetylcholine was observed under SCS and later attributed to activation of the M4 muscarine receptor. Moreover, low doses of muscarinic receptor agonists led to amplification of the SCS effects in rats, and it was shown that serotonergic pain-modulating descending pathways were involved in this effect.

Moreover, supraspinal centers are also engaged in the effect of SCS. Here, in particular, a dorsal column–brainstem–spinal loop is of importance. Barchini et al recently addressed the question of the relative proportions of supraspinal and segmental mechanisms in SCS effects. They studied the effect of SCS on neuropathic pain after lesioning the dorsal columns and stimulating rostral and caudal to the lesion under the influence of different receptor antagonists. They found that segmental as well as supraspinal mechanisms contribute to the effects of SCS and that stimulation rostral and caudal to the lesion leads to activation of different synaptic circuits and transmitter systems.

The question of how stimulation of the spinal ganglia and SCS differ clinically and electrophysiologically was studied by Guan et al by means of single-cell electrodes in WDR neurons. They found that SCS inhibited wind-up in the WDR neurons, whereas stimulation of the spinal ganglia did not. The effect of SCS continued, at least partially, for about 30-45 minutes after cessation of the stimulation.

**Patient selection/screening, including psychological**

SCS can have diverging clinical effects in different patients. It has been known for many years that some patients do
not profit from SCS, but others do. Therefore, a two-step procedure with a test phase before implantation of the impulse generator (IPG) has become routine in most hospitals since the 1970s. It has become apparent that about 17%–20% of the patients have a negative trial result and do not proceed to IPG implantation, even when the test electrode has the optimal position and the paraesthesia coverage of the painful region is complete. Moreover, SCS effects diminish over time after IPG implantation in some patients. The extent of decrease of SCS effect over time is reported variously in the literature. Some studies state that the effect has decreased 25%–50% after 2 years, but others only see a slight loss of efficacy over time. Often technical factors such as electrode problems (dislocation, breakage) have been cited to explain the loss of efficiency. However, psychological factors also come into account with regard to both the loss of efficacy over time and a negative trial result.

Several guidelines recommend that psychological testing should be performed before SCS implant. The first aim of this testing is to rule out major psychiatric diseases such as major depression, psychosis, or substance abuse. There is a vast consensus that patients with these diagnoses should not be subjected to SCS testing. However, it remains to be determined whether there are also psychological factors below the level of severe pathology, which can negatively influence SCS efficacy. Regarding this question, the literature remains somewhat inconclusive; regarding the long-term efficiency, there are studies that find a negative correlation between the level of depression and SCS efficacy, whereas others do not. In contrast, the level of depression remains one of the functional items that can show remarkable improvements after SCS implantation. Thus, even if SCS efficacy might be slightly lower in patients with mild depression, IPG implantation might be justified because apart from pain relief, depression can also improve under SCS.

Pre- and postimplant advice to patients
Preoperatively, the indication should be considered cautiously, taking the prior conservative medical physiotherapeutic and psychotherapeutic approaches into account. Differential diagnosis also requires determining the proportions of nociceptive and neuropathic pain; for instance, by means of diagnostic nerve root blocks. SCS should be considered when the radicular (neuropathic) part of the pain outweighs the nociceptive portion (Figure 1).

Some guidelines, moreover, claim interdisciplinary decision-making before testing SCS. At least a psychological examination should be carried out before SCS implantation in any case. The psychological examination should not only contribute to decision-making about whether or not to implant the electrode, but should also prepare the patient for the postoperative course and render it easier for the patient to deal with having an implantable device.

Electrode implantation usually is performed under local anaesthesia, using percutaneous-type electrodes, which can be inserted under fluoroscopic guidance. First, the spinal canal is punctured with a Touhy needle. Once the spinal canal is reached, intraspinal localization of the needle tip is ensured by means of a saline probe, a technique that can be strongly recommended to ensure the safety of the procedure and to prevent cerebrospinal fluid leaks. Then, the electrode is advanced to the desired level. In the case of leg pain, the usual electrode position is TH10–12 (Figure 2). In thoracic pain (such as postherpetic neuralgia), the electrode position depends on the level of the pathology, and in brachial pain, final electrode position is at level C3–C6 (Figure 3). Once the electrode is in the desired position, intraoperative test simulation is performed and the patient is asked to state where he feels the stimulation-induced paresthesia. At this stage, it is most important to obtain full paresthesia coverage of the painful area. Sometimes the electrode position must be changed before the optimal paraesthesia is achieved.

The patient then proceeds to a test phase, which usually lasts about 6–12 days. Some hospitals also prefer testing under domestic circumstances. Mostly, however, testing is performed in the hospital. The patient is asked to document his or her pain scores during the test phase. The decision whether or not to implant an IPG is dependent on whether or not more than 50% pain reduction is obtained, whether quality of life and moods are improved, whether analgetic medication can be reduced, and whether the patient wants the implant.

After implantation of the IPG, reprogramming of the device often is needed one or more times. Patients should be informed that slight changes in the SCS-induced paresthesia can occur and that these can be relieved by reprogramming the device. Patients often ask whether they should avoid physical activities to avoid electrode dislocation. In our experience, the risk for electrode dislocation is highest in the first few weeks after implantation, so we would not recommend heavy lifting or intense bending of the spine in this stage. After implantation of the IPG, the analgetic medication should also be reconsidered and possibly stopped. The patient can also better determine over time which simulation pattern, intermittent or continuous, is most suitable in his situation.
Current technological developments

Burst stimulation

One new development in SCS refers to the order and frequency of impulses. De Ridder et al.\textsuperscript{35} published a series of 12 patients who had been treated by means of a “burst stimulation”. This pattern of stimulation consists in so-called “bursts” of 5 impulses of 1 ms duration followed by a 1 ms interval, applied at a frequency of 500 Hz. These 5-impulse “bursts” are applied at 40 Hz. Under this stimulation pattern, pain was strongly relieved compared with using conventional stimulation. Moreover, no stimulation-induced
paresthesia was necessary to obtain a pain-relieving effect. Furthermore, unlike “conventional” SCS, not only leg pain but also back pain was relieved.35,36

**High-frequency stimulation**

Recently, a prospective multicenter study on high-frequency SCS (continuous stimulation with 10 kHz) showed favorable results.37 In this new technique, two octrodes are implanted in a staggered manner at level TH8 down to TH12. It has been observed that not only radicular leg pain but also back pain can be treated in this way. Eighty-two patients were treated in the study. An IPG was implanted in 72 patients. The mean intensity of back pain decreased from 8.2 to 2.7 on the visual analog scale and the mean intensity of the leg pain decreased from 5.4 to 1.4. The results also remained stable after 24 months.38 One peculiarity of this stimulation technique is that no paresthesia is perceived by the patient. The effectiveness of high-frequency stimulation was explained by desensitization of hyperactive WDR neurons and with control of the wind-up phenomenon of WDR neurons. However, no experimental evidence for this assumption was provided.37 Moreover, a randomized study that compared a 5 kHz stimulation with a sham stimulation in a blinded manner did not find significant differences between the two stimulation techniques.39

At the present stage, it is probably too early to draw final conclusions on the pain-relieving efficiency of high-frequency stimulation. However, as long as there is no clear neurophysiological hypothesis explaining the intense effect and the paresthesia-free pain relief, some reservation toward this new method might be indicated.

**Position-adaptive SCS**

The intensity of the SCS-induced paresthesia is dependent on body position.40–42 Under equal technical settings of the stimulator, the paresthesia is perceived more intensely in the supine position than in an upright position. Therefore, up to now, patients had to correct changes in stimulation intensity (ie, while standing up) by means of a handheld programming device. This position dependency of the stimulation is not caused by a dislocation of the electrode. In fact, it is based on the variable thickness of the cerebrospinal fluid layer around the spinal cord. Holsheimer et al43 pointed out that the position of the spinal cord within the spinal canal exhibited considerable interindividual differences. By means of a computer model, they calculated the expected thresholds for stimulation on the basis of anatomical and radiological data. The calculated data corresponded to the thresholds measured in individual patients.43 Likewise, Abejon and Feler44 found that the impedance of the electrode is not dependent on the body position. Thus, changes in body position do not interfere with changes in the electrical conductivity of the electrode and the directly adjacent tissues.44,45

Recently, new position-adaptive stimulation devices have been introduced. These devices are able to detect whether the patient is lying down or standing. The stimulation intensity is then automatically fitted to previously set values. With this technique, there is no longer any need for the patient to adjust the stimulation intensity after changing his position.

A study with 15 patients showed that patients with automatic sensor-driven stimulation were significantly more satisfied than with manually adapted stimulation.46 A recent multicenter study with 79 patients showed functional improvements; in particular, enhanced comfort during position changes, increased physical activity, and improved sleep.47

**Novel peripheral neurostimulation techniques**

Two new developments of neurostimulation are addressed here that actually do not constitute a type of SCS, as the peripheral nerves or the dorsal root ganglion are stimulated rather than the spinal cord. However, these techniques share most of the indications and use much of the same hardware. Therefore, they should be mentioned in the context of SCS.

**Peripheral nerve field stimulation**

Stimulation of a single peripheral nerve has been employed for more than 30 years in pain treatment.48 With this technique, the affected peripheral nerve (ie, N. ulnaris) is exposed and an electrode (ie, a cuff-electrode) is placed directly adjacent to the nerve. Alternatively, a percutaneous-type electrode can be inserted under the epineurium.49
Peripheral nerve field stimulation (PNFS) is a different method. Here the electrode is placed subcutaneously, with no direct relation to a particular peripheral nerve. One of the first applications of this method was occipital nerve stimulation (ONS) for chronic migraine or chronic cluster headache. Here, however, there are different opinions about whether ONS is a peripheral nerve stimulation or a PNFS. In fact, the electrode is mostly placed adjacent to the occipital nerve in ONS, but as this is not done under visual control, this ONS is probably a form of PNFS rather than peripheral nerve stimulation.

PNFS in a way closes a therapeutic gap in neuromodulative pain treatment, as it can possibly reach the trunk more effectively than SCS. First publications on PNFS dealt with chronic abdominal pain. Later, studies concerning chronic thoracic pain, chronic low back pain, failed back surgery syndrome (FBSS), and sacroiliac joint pain also were published.

PNFS has been described in a couple of case reports, smaller cases series, and some studies with higher case numbers. A retrospective multicentre study on 111 patients with chronic low back pain, FBSS, cervical pain, postherpetic neuralgia, tension headache, and some patients with trigeminal neuralgia or thoracic pain showed that the relatively best pain relief was obtained in patients with thoracic back pain, whereas the least pain relief was seen in patients with tension headache. Pain scores in total decreased from 8.2 without stimulation to 4.0 with stimulation. The mean medication use was significantly reduced. A recent prospective multicenter study on 118 patients of PFNS on chronic low back pain showed similar results. Interestingly, pain relief by TENS does not seem to be a predictor for the success of PFNS, and pain relief elicited by PNFS seems to be stronger than in TENS. A so-called “hybrid simulation”, combining SCS and PFNS, has also been proposed for various pain syndromes. A randomized study on PFNS showed that the stimulation under standard settings is significantly more effective than at subthreshold intensity or low frequency. The advantages of PNFS are that it is less invasive and that it offers the opportunity to treat the pain syndromes that cannot be treated with SCS. Some pain syndromes, such as postherpetic neuralgia, can be treated by both PFNS and SCS, and it remains to be determined which of the two techniques offers the higher efficiency. The comparison of the effects of SCS and TENS, as a peripheral stimulation, on evoked potentials showed that the SCS effect was nearly twice as strong as that of TENS.

Dorsal root ganglion stimulation

In this technique, the electrode is placed directly adjacent to the spinal ganglion. With one electrode, paresthesia is only achieved within a single dermatome. Greater pain areas can be covered with the use of more than one electrode. The implantation technique is more challenging than that of SCS. A pilot study on 10 patients showed a mean pain relief of 70% in the first days after implantation. Energy consumption with this technique seems to be significantly less compared with SCS. A recent multicenter study on 32 patients with a 6-month follow-up showed a mean pain relief of 58%. As expected, mean pain relief was strongest in the feet and weakest in the low back. A series of eight patients with complex regional pain syndrome (CRPS) showed a decrease of mean pain scores of 62% under dorsal root ganglion stimulation. Dorsal root ganglion stimulation can be considered particularly in monoradicular pain syndromes or pain syndromes affecting a very limited number of dermatomes.

Indications

In general, SCS is indicated in refractory neuropathic pain (Table 1). Early experiences have suggested that SCS is less effective in nociceptive pain. Nonetheless, in some cases it might be difficult to differentiate between the neuropathic and the nociceptive components of pain, and an SCS trial can be justified even if there are also nociceptive components in the pain syndrome. The most frequent and best studied indication is radicular pain secondary to lumbar disc surgery (FBSS). According to a recent review, FBSS evolves in approximately 30% of patients after lumbar disc surgery. Two randomized controlled trials and numerous retrospective studies have been published for FBSS. In a crossover design, North et al studied 50 patients with FBSS who had either SCS or a revision operation. Forty-five persons were followed for 3 years. Nine of 19 patients with SCS and three of 26 patients with the reoperation had more than 50% pain relief. In the SCS group, the crossover rate was lower than in the reoperation group (5/24 versus 14/26). A study on 100 patients with FBSS and predominantly neuropathic leg pain was conducted by Kumar et al. They randomized the patients into two groups; one group had conventional analgetic therapy alone and the other group had conventional analgetic plus SCS. The earliest time for a crossover was 6 months. At that time, 48% of the patients who had been treated with SCS had more than 50% pain relief, whereas this was the case in the conservative treatment group in only 9% of the patients. Again, the crossover rate was significantly lower in the SCS group than in the conservative group (5/50 versus 32/50).
Several guidelines recommend a trial of SCS in FBSS. A systematic review found class IIb evidence for efficacy of SCS in FBSS.83

Another good and well-studied indication for SCS is CRPS (CRPS I and II). In this potentially devastating neuro-orthopedic pain syndrome the use of SCS has been studied in several observational studies and one randomized controlled trial. In this study, the effectiveness of SCS combined with a 6-month physiotherapeutic treatment protocol was compared with a physiotherapeutic treatment protocol alone. Thirty-six patients were included in the SCS group, whereas 18 patients had solely physiotherapeutic treatment. Test stimulation was successful in 24 of the 36 patients. Patients in the SCS group had a mean pain relief of 2.4 points (on an 11-point scale), whereas patients with solely physiotherapeutic treatment had pain relief of 0.2 points. These differences were statistically significant and remained stable after 1 and 2 years.84 After 3 and 5 years, however, significant differences in the treatment groups were no longer seen. In these studies, as in the primary study, an intention-to-treat analysis was carried out that included the 12 patients with the negative trial in the SCS group. Moreover, four patients in the control group had received an SCS system.85,86 Interestingly, a study by Harke et al87 had a kind of internal control. This internal control, in which the stimulator was switched off for 45 minutes, was performed every 3 months during the 35-month follow-up. Pain scores for depth pain and allodynia during these inactivity tests were 7.1/10 and 4.0/10, respectively. Under stimulation, these scores decreased to 1.7/10 and 0.03/10, respectively.87 In addition to these studies, several case series regarding the use of SCS for the treatment of CRPS have been published. A meta-analysis showed that 67% of the patients experienced pain relief of more than 50%.88

SCS has also been successfully employed in a number of neuropathic pain syndromes. Excellent results have been achieved in the treatment of postherpetic neuralgia. In 23/28 patients, pain relief from a median 9/10 on the visual analog scale to 1/10 was achieved. Complete pain relief was observed in 23 of 28 patients (82%) after 3–66 months.89 Moreover, postherpetic neuralgia has been studied in a number of larger studies with miscellaneous indications.90–92 A meta-analysis showed a success rate of 82%.93 Interestingly, SCS has also been proposed as a short-term therapy for subacute herpes zoster or beginning postherpetic neuralgia. Here, a 14-day short-term therapy with an externalized electrode led to complete and lasting pain relief in some patients.94,95

One indication for SCS that is not yet general practice is diabetic polyneuropathy. In 1996, a case series was published in which 8 of 10 patients tested were treated with SCS. Mean pain scores decreased in these patients from 7.7/10 to 2.3/10. However, pallhypesthesia and electrophysiological tests remained unchanged.96 A systematic review of SCS for diabetic polyneuropathy lists three prospective case series and one retrospective cohort study. At 1-year follow-up, 63% of the patients had more than 50% pain reduction. In addition, analgetic medication could be stopped in 60% of the patients.97 Recently, long-term effects for SCS for diabetic polyneuropathy were shown over a follow-up of 3 years.98

Successful pain treatment with SCS has been described in a single case report in a vast variety of neuropathic pain syndromes such as syringomyelia,99 post-thoracotomy neuralgia,100 recurrent neuroma,101 tethered cord syndrome,102 meralgia paresthetica,103 or even multiple sclerosis.104 Favorable outcomes have also been reported in mixed pain syndromes regarding shoulder pain105 and knee pain.106

### Table 1 Overview of indications and contraindications for spinal cord stimulation

<table>
<thead>
<tr>
<th>Indications and contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
</tr>
<tr>
<td>Neurogenic pain</td>
</tr>
<tr>
<td>Failed back surgery syndrome</td>
</tr>
<tr>
<td>Complex regional pain syndrome</td>
</tr>
<tr>
<td>(type I and II)</td>
</tr>
<tr>
<td>Radicular pain</td>
</tr>
<tr>
<td>Nerve root pain (lumbar, thoracic,</td>
</tr>
<tr>
<td>cervical)</td>
</tr>
<tr>
<td>Radiculopathy, radiculitis</td>
</tr>
<tr>
<td>Postherpetic neuralgia</td>
</tr>
<tr>
<td>Neuropathic pain secondary to</td>
</tr>
<tr>
<td>peripheral nerve injury</td>
</tr>
<tr>
<td>Intercostal neuralgia</td>
</tr>
<tr>
<td>Phantom pain</td>
</tr>
<tr>
<td>Vascular pain</td>
</tr>
<tr>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
</tr>
<tr>
<td>Morbus raynaud</td>
</tr>
<tr>
<td>Potential indications</td>
</tr>
<tr>
<td>Polyneuropathy</td>
</tr>
<tr>
<td>Deafferentation pain</td>
</tr>
<tr>
<td>Spinal cord injury</td>
</tr>
<tr>
<td>Brachial plexus injury</td>
</tr>
<tr>
<td>Contraindications</td>
</tr>
<tr>
<td>Somatic</td>
</tr>
<tr>
<td>Sepsis</td>
</tr>
<tr>
<td>Coagulopathy</td>
</tr>
<tr>
<td>Infection</td>
</tr>
<tr>
<td>Inability to understand how</td>
</tr>
<tr>
<td>SCS works and to handle the</td>
</tr>
<tr>
<td>patients</td>
</tr>
<tr>
<td>Programming device</td>
</tr>
<tr>
<td>Obliteration of the spinal canal</td>
</tr>
<tr>
<td>Psychiatric</td>
</tr>
<tr>
<td>Psychosis</td>
</tr>
<tr>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Substance abuse</td>
</tr>
<tr>
<td>Severe depression/anxiety</td>
</tr>
</tbody>
</table>

**Abbreviation:** SCS, spinal cord stimulation.
An overview of randomized controlled studies is given in Table 2.36,39,46,47,75,81,82,84,85,107–111

Safety
SCS can be considered a safe technique. The probability of sustaining permanent damage caused by an SCS trial is extremely low. The puncture of the spinal canal comprises the inherent risk of spinal bleeding and permanent neurological deficit; however, the literature lists only six reported cases of neurological deficits resulting from damage of the spinal cord. In 2010, Smith et al reported a series of four patients with paraparesis occurring after a spinal cord stimulator trial.112 Two of these patients had spinal bleeding, one patient had spinal cord injury, and in one patient a preexisting thoracic disc herniation was encountered. To rule out thoracic disc herniation or spinal stenosis, the authors advocated magnetic resonance imaging (MRI) before SCS lead insertion. In the same article, the authors quoted two additional cases of paraparesis secondary to SCS

<table>
<thead>
<tr>
<th>Table 2 Overview of randomized studies for SCS (and PNFS)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title/author</strong></td>
</tr>
<tr>
<td>Conventional SCS</td>
</tr>
<tr>
<td>PROCeSS, Kumar et al</td>
</tr>
<tr>
<td>North et al</td>
</tr>
<tr>
<td>Kemler et al</td>
</tr>
<tr>
<td>Subthreshold stimulation</td>
</tr>
<tr>
<td>Wolter et al</td>
</tr>
<tr>
<td>Adaptive stimulation</td>
</tr>
<tr>
<td>Schultz et al</td>
</tr>
<tr>
<td>Schade et al</td>
</tr>
<tr>
<td>High-frequency stimulation</td>
</tr>
<tr>
<td>Perruchoud et al</td>
</tr>
<tr>
<td>Burst stimulation</td>
</tr>
<tr>
<td>De Ridder et al</td>
</tr>
<tr>
<td>PNFS</td>
</tr>
<tr>
<td>McRoberts et al</td>
</tr>
</tbody>
</table>

Abbreviations: SCS, spinal cord stimulation; PNFS, peripheral nerve field stimulation; CMM, conventional medical management; HF SCS, high-frequency SCS; VAS, visual analog scale; vs, versus.
lead insertion: one case of dural puncture and intramedullary lead placement\textsuperscript{113} and another case of needle penetration in the cervical cord.\textsuperscript{114} However, neurological deficit developing in the course of time, as a consequence of scarring,\textsuperscript{115–117} of an epidural mass,\textsuperscript{118} or of a foreign body reaction\textsuperscript{119} has also been reported in case reports. Given the fact that several hundred thousand SCS devices have been implanted worldwide since its advent, even admitting that neurological deficits after SCS might be underreported, this hints at a low probability of permanent neurologic deficit to SCS electrode implantation.

Infection can occur after SCS implantation. The incidence is reported between 3.4\%\textsuperscript{62} and 6\%.\textsuperscript{120} Usually, cases of infection have an uneventful benign course when the electrodes are removed and antibiotic therapy is initiated.

The probability of unscheduled additional revision operations caused by hardware problems, such as lead dislocation or lead breakage, is apparently high. A systematic review of SCS for FBSS or chronic back and leg pain found that 43\% of the patients had one or more complications with SCS. Most of these were lead problems (lead dislocation). Infections were encountered in 6\% of the patients and cerebral spinal fluid leaks in 7\%.\textsuperscript{120} A monocentric study on 707 patients found no patient with permanent neurologic deficit. However, hardware failures in this series occurred in 38\% of the patients (22.6\% lead migration, 9.5\% lead connection failure, and 6\% lead breakage).\textsuperscript{121} Another large study on hardware failure modes found a significantly higher revision rate in cervical than in thoracolumbar SCS systems. Again, lead migration was the most frequent cause of repeat surgery\textsuperscript{122} (Table 3).

The use of paddle leads that have to be implanted surgically via laminotomy has been advocated for patients with a history of lead migration. A recent study showed that the initial complication rate was higher with paddle leads compared with percutaneous leads, but the longer-term reoperation rate was significantly lower.\textsuperscript{123}

### Table 3 Possible complications of spinal cord stimulation

<table>
<thead>
<tr>
<th>Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hardware-related</td>
</tr>
<tr>
<td>Lead migration</td>
</tr>
<tr>
<td>Lead breakage</td>
</tr>
<tr>
<td>Connection failure</td>
</tr>
<tr>
<td>Battery depletion</td>
</tr>
<tr>
<td>Unwanted paresthesia</td>
</tr>
<tr>
<td>Pain at the impulse generator site</td>
</tr>
<tr>
<td>Not hardware-related</td>
</tr>
<tr>
<td>Hematoma, seroma infection</td>
</tr>
<tr>
<td>Cerebrospinal fluid loss</td>
</tr>
<tr>
<td>Neurological deficit</td>
</tr>
</tbody>
</table>

Interaction of SCS with diathermy, cardiac pacemakers, ultrasound, or MRI is possible and can lead to unwanted paresthesia or dysfunction of the system. In particular, MRI may exert forces on the implanted material and therefore may induce the risk of, for example, intraspinal bleeding. Last year a MRI-compatible SCS system was newly introduced. However, a recent study showed that as with conventional SCS systems using an adapted protocol, a MRI (1.5 T) can be performed safely.\textsuperscript{124}

### Long-term outcomes and place in therapy

Outcomes of SCS therapy have considerably improved over the course of the last 30 years. Although in the 1970s about 40\% of the patients achieved pain relief of more than 50\%, this percentage in recent studies is more than 70\%. Proper patient selection and meticulous preoperative diagnostics, including psychological assessment, are crucial for the success of the method. Moreover, more knowledge regarding promising indications has been gathered over the course of the years. SCS therapy today is not necessarily seen as a therapy of last resort, but as an effective possibility to overcome pain that would otherwise be difficult to treat. Unsuccessful conventional medical management is regarded as a criterion in favor of an SCS trial. However, most of the guidelines do not state whether or not opioids, particularly strong opioids, should be employed. Today, many pain physicians probably would not insist on a prior therapeutic attempt with highly potent opioids, and SCS would be ranked in the therapeutic order between weak and strong opioids. At any rate, the disadvantages of long-term opioid therapy\textsuperscript{125} should be weighed against those of SCS therapy. SCS can certainly be used together with analgetic medications, but in an optimal setting, SCS can make pain medication redundant. Often, however, patients continue to take analgetic medications. For instance, in a study on 60 consecutive patients, 16\% of the patients took no analgetics at all after SCS implantation, whereas more than half of the patients took two or more different analgetics.\textsuperscript{31}

Another important point is the duration of conservative therapy before SCS implantation. Kumar et al observed an inverse correlation between the long-term success rate and the time interval between the onset of the chronic pain syndrome and SCS implantation. They noted that the success rate in patients who received their SCS system within the first 2 years of their pain syndrome was 85\%, whereas the success rate was 9\% in patients with a more than 15-year history of chronic pain.\textsuperscript{126,127} As a consequence, an SCS trial should be performed within the first 2 years.
after onset of pain. In contrast, also less invasive therapies should have been tried before an SCS trial, so realistically, SCS will rarely be applied earlier than 6–12 months from the onset of pain. Anyway, also a recent review concluded that SCS for CRPS “should be considered earlier than last resort therapy.”

**Conclusion**

SCS is an effective treatment option for neuropathic pain. Technical advancement of SCS has led to improvement in stimulation patterns adapted to the patients’ needs. SCS for neuropathic pain is still underused. Careful preoperative diagnosis and proper patient selection is most important for the success of the methods.

**Disclosure**

The author reports no conflicts of interest in this work.

**References**


